Jubilant Pharmova appoints Daniel J. O Connor as CEO of Jubilant Therapeutics
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
The study, titled “A Large-Scale Efficacy Trial of a Resilience Training Program for First Responders,” will enroll 800 first responders in New York and Texas
The clearance for TELLTALE positions Transmural Systems at the forefront of next-generation electrosurgical solutions for structural heart interventions
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The Signia Circular Stapler is the only circular stapler on the market with integrated leak testing and features designed to minimize risk
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Desai is currently serving the company as Group Finance Controller
Subscribe To Our Newsletter & Stay Updated